MỐI LIÊN QUAN GIỮA ĐA HÌNH rs1799752 CỦA GEN ACE VÀ ĐÁP ỨNG ĐIỀU TRỊ ERYTHROPOIETIN Ở BỆNH NHÂN LỌC MÁU CHU KỲ

Abstract

  Background: Anemia is a common complication in patients with end-stage kidney disease, associated with increased mortality and reduced quality of life. Response to erythropoietin therapy varies among individuals in which ACE gene polymorphisms have been suggested as potential contributing factors; however, data on the rs1799752 polymorphism in Vietnam remain limited. Objectives: 1. To determine the prevalence and characteristics of anemia in maintenance hemodialysis patients; 2. To determine the prevalence of the ACE rs1799752 polymorphism and to evaluate its association with response to erythropoietin therapy. Materials and methods: This longitudinal study included 83 patients with stage 5 chronic kidney disease undergoing maintenance hemodialysis at Can Tho Central General Hospital. Patients were followed for 6 months during the study period from 2024 to 2026. The rs1799752 genotype was determined using RFLP-PCR. Hematological and biochemical parameters, as well as erythropoietin dosage, were collected and monitored to assess treatment response based on the ability to achieve and maintain target hemoglobin levels. Results: The frequencies of the II, ID, and DD genotypes were 51.8%, 36.1%, 12.1%. The II genotype was independently associated with achieving the target Hb level (OR = 3.33, 95% CI: 1.104 − 10.045; p < 0.05). Conclusions: The ACE gene rs1799752 polymorphism shows diverse distribution among maintenance hemodialysis patients and is associated with the response to erythropoietin therapy.